Evidence map›Paper›PMID 40658311›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.

Keiji Sugiyama, Sacheen Kumar, Asif Chaudry, Nikhil Patel, Pranav Patel, David Cunningham, Naureen Starling, Sheela Rao, Charlotte Fribbens, Ian Chau

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Keiji SugiyamaGastrointestinal Unit, Department of Medicine, The Royal Marsden Hospital, Downs Road, Sutton, London, Surrey, UK.
Sacheen KumarDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UK.
Asif ChaudryDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UK.
Nikhil PatelDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UK.
Pranav PatelDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UK.
David CunninghamGastrointestinal Unit, Department of Medicine, The Royal Marsden Hospital, Downs Road, Sutton, London, Surrey, UK.
Naureen StarlingGastrointestinal Unit, Department of Medicine, The Royal Marsden Hospital, Downs Road, Sutton, London, Surrey, UK.
Sheela RaoGastrointestinal Unit, Department of Medicine, The Royal Marsden Hospital, Downs Road, Sutton, London, Surrey, UK.
Charlotte FribbensGastrointestinal Unit, Department of Medicine, The Royal Marsden Hospital, Downs Road, Sutton, London, Surrey, UK.
Ian ChauGastrointestinal Unit, Department of Medicine, The Royal Marsden Hospital, Downs Road, Sutton, London, Surrey, UK. ian.chau@rmh.nhs.uk.ORCID 0000-0003-0286-8703

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPerioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for locally advanced oesophagogastric adenocarcinoma (LA-OGA) in Western countries. However, completing treatment is challenging for patients, particularly in the postoperative setting. This study investigated the impact of adjuvant chemotherapy (ACT) administration and treatment completion on survival outcomes in patients receiving FLOT.

methodsCharts of LA-OGA patients treated from 2017 to 2023 were retrospectively reviewed. Survival was analysed using Kaplan-Meier and restricted mean survival time (RMST) analyses, with propensity score matching (PSM) adjustments. Subgroup analyses were stratified by pathological nodal status and tumour regression grade (Mandard TRG). The primary endpoint was 3-year overall survival (OS).

resultsThe study included 233 patients, among whom 62.4% completed the full perioperative FLOT regimen and 21% did not receive ACT. After PSM adjustment, 3-year OS for patients who completed and those who did not complete perioperative therapy was 69% and 57%, respectively (p = 0.09). The 3-year OS was 81% and 52% for patients who did and did not receive ACT, respectively (p = 0.01). In multivariate analysis, completion of perioperative FLOT was independently associated with improved OS (p = 0.04). Survival improvement with ACT was observed in the ypN-positive subgroup but not in the ypN-negative subgroup.

conclusionsPerioperative FLOT administration is recommended as the standard of care for LA-OGA. The survival impact of ACT might be influenced by pathological lymph node metastasis.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsStomach NeoplasmsAdultAgedChemotherapy, AdjuvantDocetaxelFemaleFluorouracilHumansLeucovorinMaleMiddle AgedOxaliplatinRetrospective StudiesDocetaxelFluorouracilLeucovorinOxaliplatinAdjuvant therapyEsophageal cancerGastric cancerNeoadjuvant therapy

Identifiers

PMID40658311
PMCPMC12378138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.